nodes	percent_of_prediction	percent_of_DWPC	metapath
Ceftazidime—Phlebitis—Carboplatin—bone cancer	0.0375	0.0375	CcSEcCtD
Ceftazidime—Nephropathy toxic—Cisplatin—bone cancer	0.0228	0.0228	CcSEcCtD
Ceftazidime—Reaction gastrointestinal—Methotrexate—bone cancer	0.0215	0.0215	CcSEcCtD
Ceftazidime—Prothrombin level increased—Epirubicin—bone cancer	0.0164	0.0164	CcSEcCtD
Ceftazidime—Prothrombin level increased—Doxorubicin—bone cancer	0.0151	0.0151	CcSEcCtD
Ceftazidime—Nephropathy—Methotrexate—bone cancer	0.0151	0.0151	CcSEcCtD
Ceftazidime—Pain—Carboplatin—bone cancer	0.0136	0.0136	CcSEcCtD
Ceftazidime—Body temperature increased—Carboplatin—bone cancer	0.0126	0.0126	CcSEcCtD
Ceftazidime—Skin exfoliation—Cisplatin—bone cancer	0.0125	0.0125	CcSEcCtD
Ceftazidime—Local reaction—Epirubicin—bone cancer	0.0121	0.0121	CcSEcCtD
Ceftazidime—Local reaction—Doxorubicin—bone cancer	0.0112	0.0112	CcSEcCtD
Ceftazidime—Encephalopathy—Methotrexate—bone cancer	0.0112	0.0112	CcSEcCtD
Ceftazidime—Phlebitis—Cisplatin—bone cancer	0.011	0.011	CcSEcCtD
Ceftazidime—Thrombocytosis—Epirubicin—bone cancer	0.0108	0.0108	CcSEcCtD
Ceftazidime—Oral candidiasis—Epirubicin—bone cancer	0.0106	0.0106	CcSEcCtD
Ceftazidime—Haemolytic anaemia—Cisplatin—bone cancer	0.0105	0.0105	CcSEcCtD
Ceftazidime—Thrombocytosis—Doxorubicin—bone cancer	0.00999	0.00999	CcSEcCtD
Ceftazidime—Oral candidiasis—Doxorubicin—bone cancer	0.00978	0.00978	CcSEcCtD
Ceftazidime—Dermatitis atopic—Epirubicin—bone cancer	0.00907	0.00907	CcSEcCtD
Ceftazidime—Dermatitis atopic—Doxorubicin—bone cancer	0.00839	0.00839	CcSEcCtD
Ceftazidime—Injection site pain—Epirubicin—bone cancer	0.00822	0.00822	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Methotrexate—bone cancer	0.00789	0.00789	CcSEcCtD
Ceftazidime—Pancytopenia—Cisplatin—bone cancer	0.00779	0.00779	CcSEcCtD
Ceftazidime—Injection site pain—Doxorubicin—bone cancer	0.00761	0.00761	CcSEcCtD
Ceftazidime—Inflammation—Methotrexate—bone cancer	0.00739	0.00739	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Epirubicin—bone cancer	0.00738	0.00738	CcSEcCtD
Ceftazidime—Renal failure—Cisplatin—bone cancer	0.00719	0.00719	CcSEcCtD
Ceftazidime—Vaginal inflammation—Methotrexate—bone cancer	0.00717	0.00717	CcSEcCtD
Ceftazidime—Inflammation—Epirubicin—bone cancer	0.00692	0.00692	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Cisplatin—bone cancer	0.00691	0.00691	CcSEcCtD
Ceftazidime—Skin exfoliation—Methotrexate—bone cancer	0.00685	0.00685	CcSEcCtD
Ceftazidime—Hyperbilirubinaemia—Doxorubicin—bone cancer	0.00683	0.00683	CcSEcCtD
Ceftazidime—Vaginal infection—Methotrexate—bone cancer	0.00677	0.00677	CcSEcCtD
Ceftazidime—Aplastic anaemia—Methotrexate—bone cancer	0.00673	0.00673	CcSEcCtD
Ceftazidime—Vaginal inflammation—Epirubicin—bone cancer	0.00671	0.00671	CcSEcCtD
Ceftazidime—Coma—Methotrexate—bone cancer	0.00655	0.00655	CcSEcCtD
Ceftazidime—Colitis—Epirubicin—bone cancer	0.00644	0.00644	CcSEcCtD
Ceftazidime—Skin exfoliation—Epirubicin—bone cancer	0.00641	0.00641	CcSEcCtD
Ceftazidime—Candida infection—Epirubicin—bone cancer	0.00641	0.00641	CcSEcCtD
Ceftazidime—Inflammation—Doxorubicin—bone cancer	0.0064	0.0064	CcSEcCtD
Ceftazidime—Vaginal infection—Epirubicin—bone cancer	0.00634	0.00634	CcSEcCtD
Ceftazidime—Aplastic anaemia—Epirubicin—bone cancer	0.0063	0.0063	CcSEcCtD
Ceftazidime—Vaginal inflammation—Doxorubicin—bone cancer	0.00621	0.00621	CcSEcCtD
Ceftazidime—Coma—Epirubicin—bone cancer	0.00613	0.00613	CcSEcCtD
Ceftazidime—Flushing—Cisplatin—bone cancer	0.00609	0.00609	CcSEcCtD
Ceftazidime—Thrombophlebitis—Methotrexate—bone cancer	0.00601	0.00601	CcSEcCtD
Ceftazidime—Colitis—Doxorubicin—bone cancer	0.00596	0.00596	CcSEcCtD
Ceftazidime—Skin exfoliation—Doxorubicin—bone cancer	0.00593	0.00593	CcSEcCtD
Ceftazidime—Candida infection—Doxorubicin—bone cancer	0.00593	0.00593	CcSEcCtD
Ceftazidime—Immune system disorder—Cisplatin—bone cancer	0.00593	0.00593	CcSEcCtD
Ceftazidime—Vaginal infection—Doxorubicin—bone cancer	0.00586	0.00586	CcSEcCtD
Ceftazidime—Aplastic anaemia—Doxorubicin—bone cancer	0.00583	0.00583	CcSEcCtD
Ceftazidime—Coma—Doxorubicin—bone cancer	0.00567	0.00567	CcSEcCtD
Ceftazidime—Phlebitis—Epirubicin—bone cancer	0.00565	0.00565	CcSEcCtD
Ceftazidime—Thrombophlebitis—Epirubicin—bone cancer	0.00563	0.00563	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Epirubicin—bone cancer	0.00557	0.00557	CcSEcCtD
Ceftazidime—Vision blurred—Cisplatin—bone cancer	0.00538	0.00538	CcSEcCtD
Ceftazidime—Tremor—Cisplatin—bone cancer	0.00535	0.00535	CcSEcCtD
Ceftazidime—Lethargy—Methotrexate—bone cancer	0.00531	0.00531	CcSEcCtD
Ceftazidime—Phlebitis—Doxorubicin—bone cancer	0.00523	0.00523	CcSEcCtD
Ceftazidime—Hot flush—Epirubicin—bone cancer	0.00521	0.00521	CcSEcCtD
Ceftazidime—Thrombophlebitis—Doxorubicin—bone cancer	0.00521	0.00521	CcSEcCtD
Ceftazidime—Menopausal symptoms—Epirubicin—bone cancer	0.00516	0.00516	CcSEcCtD
Ceftazidime—Hepatic function abnormal—Doxorubicin—bone cancer	0.00516	0.00516	CcSEcCtD
Ceftazidime—Renal impairment—Epirubicin—bone cancer	0.00512	0.00512	CcSEcCtD
Ceftazidime—Leukopenia—Cisplatin—bone cancer	0.00511	0.00511	CcSEcCtD
Ceftazidime—Lethargy—Epirubicin—bone cancer	0.00497	0.00497	CcSEcCtD
Ceftazidime—Convulsion—Cisplatin—bone cancer	0.00495	0.00495	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00483	0.00483	CcSEcCtD
Ceftazidime—Hot flush—Doxorubicin—bone cancer	0.00482	0.00482	CcSEcCtD
Ceftazidime—Menopausal symptoms—Doxorubicin—bone cancer	0.00478	0.00478	CcSEcCtD
Ceftazidime—Renal impairment—Doxorubicin—bone cancer	0.00474	0.00474	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.00469	0.00469	CcSEcCtD
Ceftazidime—Anaphylactic shock—Cisplatin—bone cancer	0.00466	0.00466	CcSEcCtD
Ceftazidime—Lethargy—Doxorubicin—bone cancer	0.0046	0.0046	CcSEcCtD
Ceftazidime—Nervous system disorder—Cisplatin—bone cancer	0.00457	0.00457	CcSEcCtD
Ceftazidime—Thrombocytopenia—Cisplatin—bone cancer	0.00457	0.00457	CcSEcCtD
Ceftazidime—Skin disorder—Cisplatin—bone cancer	0.00453	0.00453	CcSEcCtD
Ceftazidime—Eosinophilia—Methotrexate—bone cancer	0.00445	0.00445	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.00439	0.00439	CcSEcCtD
Ceftazidime—Hypotension—Cisplatin—bone cancer	0.00436	0.00436	CcSEcCtD
Ceftazidime—Pancytopenia—Methotrexate—bone cancer	0.00427	0.00427	CcSEcCtD
Ceftazidime—Neutropenia—Methotrexate—bone cancer	0.00421	0.00421	CcSEcCtD
Ceftazidime—Paraesthesia—Cisplatin—bone cancer	0.00419	0.00419	CcSEcCtD
Ceftazidime—Eosinophilia—Epirubicin—bone cancer	0.00417	0.00417	CcSEcCtD
Ceftazidime—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00406	0.00406	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Cisplatin—bone cancer	0.00403	0.00403	CcSEcCtD
Ceftazidime—Infestation NOS—Methotrexate—bone cancer	0.00401	0.00401	CcSEcCtD
Ceftazidime—Infestation—Methotrexate—bone cancer	0.00401	0.00401	CcSEcCtD
Ceftazidime—Pancytopenia—Epirubicin—bone cancer	0.004	0.004	CcSEcCtD
Ceftazidime—Pain—Cisplatin—bone cancer	0.00399	0.00399	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.00398	0.00398	CcSEcCtD
Ceftazidime—Renal failure—Methotrexate—bone cancer	0.00394	0.00394	CcSEcCtD
Ceftazidime—Neutropenia—Epirubicin—bone cancer	0.00394	0.00394	CcSEcCtD
Ceftazidime—Eosinophilia—Doxorubicin—bone cancer	0.00386	0.00386	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Methotrexate—bone cancer	0.00379	0.00379	CcSEcCtD
Ceftazidime—Infestation NOS—Epirubicin—bone cancer	0.00375	0.00375	CcSEcCtD
Ceftazidime—Infestation—Epirubicin—bone cancer	0.00375	0.00375	CcSEcCtD
Ceftazidime—Agranulocytosis—Methotrexate—bone cancer	0.00374	0.00374	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.00372	0.00372	CcSEcCtD
Ceftazidime—Pancytopenia—Doxorubicin—bone cancer	0.0037	0.0037	CcSEcCtD
Ceftazidime—Renal failure—Epirubicin—bone cancer	0.00369	0.00369	CcSEcCtD
Ceftazidime—Body temperature increased—Cisplatin—bone cancer	0.00369	0.00369	CcSEcCtD
Ceftazidime—Jaundice—Epirubicin—bone cancer	0.00366	0.00366	CcSEcCtD
Ceftazidime—Neutropenia—Doxorubicin—bone cancer	0.00364	0.00364	CcSEcCtD
Ceftazidime—Haemoglobin—Methotrexate—bone cancer	0.00362	0.00362	CcSEcCtD
Ceftazidime—Haemorrhage—Methotrexate—bone cancer	0.0036	0.0036	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Epirubicin—bone cancer	0.00355	0.00355	CcSEcCtD
Ceftazidime—Agranulocytosis—Epirubicin—bone cancer	0.0035	0.0035	CcSEcCtD
Ceftazidime—Infestation NOS—Doxorubicin—bone cancer	0.00347	0.00347	CcSEcCtD
Ceftazidime—Infestation—Doxorubicin—bone cancer	0.00347	0.00347	CcSEcCtD
Ceftazidime—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00344	0.00344	CcSEcCtD
Ceftazidime—Hypersensitivity—Cisplatin—bone cancer	0.00344	0.00344	CcSEcCtD
Ceftazidime—Renal failure—Doxorubicin—bone cancer	0.00341	0.00341	CcSEcCtD
Ceftazidime—Erythema multiforme—Methotrexate—bone cancer	0.00341	0.00341	CcSEcCtD
Ceftazidime—Haemoglobin—Epirubicin—bone cancer	0.00339	0.00339	CcSEcCtD
Ceftazidime—Jaundice—Doxorubicin—bone cancer	0.00339	0.00339	CcSEcCtD
Ceftazidime—Haemorrhage—Epirubicin—bone cancer	0.00337	0.00337	CcSEcCtD
Ceftazidime—Hepatobiliary disease—Doxorubicin—bone cancer	0.00329	0.00329	CcSEcCtD
Ceftazidime—Angiopathy—Methotrexate—bone cancer	0.00327	0.00327	CcSEcCtD
Ceftazidime—Immune system disorder—Methotrexate—bone cancer	0.00325	0.00325	CcSEcCtD
Ceftazidime—Agranulocytosis—Doxorubicin—bone cancer	0.00324	0.00324	CcSEcCtD
Ceftazidime—Diarrhoea—Cisplatin—bone cancer	0.00319	0.00319	CcSEcCtD
Ceftazidime—Erythema multiforme—Epirubicin—bone cancer	0.00319	0.00319	CcSEcCtD
Ceftazidime—Haemoglobin—Doxorubicin—bone cancer	0.00313	0.00313	CcSEcCtD
Ceftazidime—Flushing—Epirubicin—bone cancer	0.00313	0.00313	CcSEcCtD
Ceftazidime—Haemorrhage—Doxorubicin—bone cancer	0.00312	0.00312	CcSEcCtD
Ceftazidime—Dysgeusia—Methotrexate—bone cancer	0.00307	0.00307	CcSEcCtD
Ceftazidime—Angiopathy—Epirubicin—bone cancer	0.00306	0.00306	CcSEcCtD
Ceftazidime—Immune system disorder—Epirubicin—bone cancer	0.00304	0.00304	CcSEcCtD
Ceftazidime—Vomiting—Cisplatin—bone cancer	0.00296	0.00296	CcSEcCtD
Ceftazidime—Vision blurred—Methotrexate—bone cancer	0.00295	0.00295	CcSEcCtD
Ceftazidime—Erythema multiforme—Doxorubicin—bone cancer	0.00295	0.00295	CcSEcCtD
Ceftazidime—Rash—Cisplatin—bone cancer	0.00294	0.00294	CcSEcCtD
Ceftazidime—Dermatitis—Cisplatin—bone cancer	0.00294	0.00294	CcSEcCtD
Ceftazidime—Flushing—Doxorubicin—bone cancer	0.00289	0.00289	CcSEcCtD
Ceftazidime—Dysgeusia—Epirubicin—bone cancer	0.00287	0.00287	CcSEcCtD
Ceftazidime—Angiopathy—Doxorubicin—bone cancer	0.00283	0.00283	CcSEcCtD
Ceftazidime—Immune system disorder—Doxorubicin—bone cancer	0.00282	0.00282	CcSEcCtD
Ceftazidime—Leukopenia—Methotrexate—bone cancer	0.00281	0.00281	CcSEcCtD
Ceftazidime—Nausea—Cisplatin—bone cancer	0.00277	0.00277	CcSEcCtD
Ceftazidime—Vision blurred—Epirubicin—bone cancer	0.00276	0.00276	CcSEcCtD
Ceftazidime—Convulsion—Methotrexate—bone cancer	0.00272	0.00272	CcSEcCtD
Ceftazidime—Agitation—Epirubicin—bone cancer	0.0027	0.0027	CcSEcCtD
Ceftazidime—Dysgeusia—Doxorubicin—bone cancer	0.00266	0.00266	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00265	0.00265	CcSEcCtD
Ceftazidime—Leukopenia—Epirubicin—bone cancer	0.00263	0.00263	CcSEcCtD
Ceftazidime—Anaphylactic shock—Methotrexate—bone cancer	0.00256	0.00256	CcSEcCtD
Ceftazidime—Vision blurred—Doxorubicin—bone cancer	0.00256	0.00256	CcSEcCtD
Ceftazidime—Convulsion—Epirubicin—bone cancer	0.00254	0.00254	CcSEcCtD
Ceftazidime—Nervous system disorder—Methotrexate—bone cancer	0.00251	0.00251	CcSEcCtD
Ceftazidime—Thrombocytopenia—Methotrexate—bone cancer	0.00251	0.00251	CcSEcCtD
Ceftazidime—Agitation—Doxorubicin—bone cancer	0.00249	0.00249	CcSEcCtD
Ceftazidime—Skin disorder—Methotrexate—bone cancer	0.00249	0.00249	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00248	0.00248	CcSEcCtD
Ceftazidime—Leukopenia—Doxorubicin—bone cancer	0.00243	0.00243	CcSEcCtD
Ceftazidime—Anaphylactic shock—Epirubicin—bone cancer	0.00239	0.00239	CcSEcCtD
Ceftazidime—Hypotension—Methotrexate—bone cancer	0.00239	0.00239	CcSEcCtD
Ceftazidime—Convulsion—Doxorubicin—bone cancer	0.00235	0.00235	CcSEcCtD
Ceftazidime—Nervous system disorder—Epirubicin—bone cancer	0.00235	0.00235	CcSEcCtD
Ceftazidime—Thrombocytopenia—Epirubicin—bone cancer	0.00234	0.00234	CcSEcCtD
Ceftazidime—Skin disorder—Epirubicin—bone cancer	0.00233	0.00233	CcSEcCtD
Ceftazidime—Paraesthesia—Methotrexate—bone cancer	0.0023	0.0023	CcSEcCtD
Ceftazidime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.0023	0.0023	CcSEcCtD
Ceftazidime—Hypotension—Epirubicin—bone cancer	0.00224	0.00224	CcSEcCtD
Ceftazidime—Anaphylactic shock—Doxorubicin—bone cancer	0.00222	0.00222	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Methotrexate—bone cancer	0.00221	0.00221	CcSEcCtD
Ceftazidime—Pain—Methotrexate—bone cancer	0.00219	0.00219	CcSEcCtD
Ceftazidime—Nervous system disorder—Doxorubicin—bone cancer	0.00217	0.00217	CcSEcCtD
Ceftazidime—Thrombocytopenia—Doxorubicin—bone cancer	0.00217	0.00217	CcSEcCtD
Ceftazidime—Skin disorder—Doxorubicin—bone cancer	0.00215	0.00215	CcSEcCtD
Ceftazidime—Paraesthesia—Epirubicin—bone cancer	0.00215	0.00215	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Methotrexate—bone cancer	0.00209	0.00209	CcSEcCtD
Ceftazidime—Hypotension—Doxorubicin—bone cancer	0.00207	0.00207	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Epirubicin—bone cancer	0.00207	0.00207	CcSEcCtD
Ceftazidime—Pain—Epirubicin—bone cancer	0.00205	0.00205	CcSEcCtD
Ceftazidime—Urticaria—Methotrexate—bone cancer	0.00203	0.00203	CcSEcCtD
Ceftazidime—Body temperature increased—Methotrexate—bone cancer	0.00202	0.00202	CcSEcCtD
Ceftazidime—Abdominal pain—Methotrexate—bone cancer	0.00202	0.00202	CcSEcCtD
Ceftazidime—Paraesthesia—Doxorubicin—bone cancer	0.00199	0.00199	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Epirubicin—bone cancer	0.00196	0.00196	CcSEcCtD
Ceftazidime—Gastrointestinal disorder—Doxorubicin—bone cancer	0.00191	0.00191	CcSEcCtD
Ceftazidime—Urticaria—Epirubicin—bone cancer	0.0019	0.0019	CcSEcCtD
Ceftazidime—Pain—Doxorubicin—bone cancer	0.00189	0.00189	CcSEcCtD
Ceftazidime—Abdominal pain—Epirubicin—bone cancer	0.00189	0.00189	CcSEcCtD
Ceftazidime—Body temperature increased—Epirubicin—bone cancer	0.00189	0.00189	CcSEcCtD
Ceftazidime—Hypersensitivity—Methotrexate—bone cancer	0.00189	0.00189	CcSEcCtD
Ceftazidime—Gastrointestinal pain—Doxorubicin—bone cancer	0.00181	0.00181	CcSEcCtD
Ceftazidime—Pruritus—Methotrexate—bone cancer	0.00181	0.00181	CcSEcCtD
Ceftazidime—Hypersensitivity—Epirubicin—bone cancer	0.00176	0.00176	CcSEcCtD
Ceftazidime—Urticaria—Doxorubicin—bone cancer	0.00176	0.00176	CcSEcCtD
Ceftazidime—Abdominal pain—Doxorubicin—bone cancer	0.00175	0.00175	CcSEcCtD
Ceftazidime—Body temperature increased—Doxorubicin—bone cancer	0.00175	0.00175	CcSEcCtD
Ceftazidime—Diarrhoea—Methotrexate—bone cancer	0.00175	0.00175	CcSEcCtD
Ceftazidime—Pruritus—Epirubicin—bone cancer	0.00169	0.00169	CcSEcCtD
Ceftazidime—Dizziness—Methotrexate—bone cancer	0.00169	0.00169	CcSEcCtD
Ceftazidime—Diarrhoea—Epirubicin—bone cancer	0.00164	0.00164	CcSEcCtD
Ceftazidime—Hypersensitivity—Doxorubicin—bone cancer	0.00163	0.00163	CcSEcCtD
Ceftazidime—Vomiting—Methotrexate—bone cancer	0.00163	0.00163	CcSEcCtD
Ceftazidime—Rash—Methotrexate—bone cancer	0.00161	0.00161	CcSEcCtD
Ceftazidime—Dermatitis—Methotrexate—bone cancer	0.00161	0.00161	CcSEcCtD
Ceftazidime—Headache—Methotrexate—bone cancer	0.0016	0.0016	CcSEcCtD
Ceftazidime—Dizziness—Epirubicin—bone cancer	0.00158	0.00158	CcSEcCtD
Ceftazidime—Pruritus—Doxorubicin—bone cancer	0.00157	0.00157	CcSEcCtD
Ceftazidime—Vomiting—Epirubicin—bone cancer	0.00152	0.00152	CcSEcCtD
Ceftazidime—Nausea—Methotrexate—bone cancer	0.00152	0.00152	CcSEcCtD
Ceftazidime—Diarrhoea—Doxorubicin—bone cancer	0.00152	0.00152	CcSEcCtD
Ceftazidime—Rash—Epirubicin—bone cancer	0.00151	0.00151	CcSEcCtD
Ceftazidime—Dermatitis—Epirubicin—bone cancer	0.00151	0.00151	CcSEcCtD
Ceftazidime—Headache—Epirubicin—bone cancer	0.0015	0.0015	CcSEcCtD
Ceftazidime—Dizziness—Doxorubicin—bone cancer	0.00147	0.00147	CcSEcCtD
Ceftazidime—Nausea—Epirubicin—bone cancer	0.00142	0.00142	CcSEcCtD
Ceftazidime—Vomiting—Doxorubicin—bone cancer	0.00141	0.00141	CcSEcCtD
Ceftazidime—Rash—Doxorubicin—bone cancer	0.0014	0.0014	CcSEcCtD
Ceftazidime—Dermatitis—Doxorubicin—bone cancer	0.0014	0.0014	CcSEcCtD
Ceftazidime—Headache—Doxorubicin—bone cancer	0.00139	0.00139	CcSEcCtD
Ceftazidime—Nausea—Doxorubicin—bone cancer	0.00132	0.00132	CcSEcCtD
